| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcc7df8a0744f77b99c4e99a5d0eaf0a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-24 |
| filingDate |
2006-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aa2fd67cd6d4eabf89d83ab176c29c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71114945dbecfbfba4a1bcefe6978891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fa3bda2f47e8ae6066df85149b27b0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b13403a18d39ff34b150522098ade84d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0463448795dd815e71afeaa002a16b8e |
| publicationDate |
2013-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2478612-C2 |
| titleOfInvention |
Crystalline forms of tigecycline and method for preparing them |
| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to a crystalline form of tigecycline I characterised by the fact that an X-ray picture formed by powder X-ray diffraction shows diffraction peaks at the angles of 2θ 5.2° and 11.1°, as well as a diffraction peak at the angle of 29 8.3° and a diffraction peak at the angle of 2θ 24.8°. The crystalline form of tigecycline I is used for preparing pharmaceutical formulations, for treating bacterial diseases. n EFFECT: preparing the solid crystalline form of tigecycline possessing the improved stability characteristics. n 8 cl, 9 dwg, 4 tbl, 10 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764723-C2 |
| priorityDate |
2005-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |